HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK To Overhaul Health Claims Approval In Event of 'No Deal' Brexit

Executive Summary

In the event of a no deal Brexit, new health claims approved by EFSA will not be valid in the UK. Firms will need to seek approval from the new UKNHCC body.

You may also be interested in...



Blood Glucose Health Claim For Dietary Supplement Set For UK Assessment

Ascarit is seeking UK approval for the health claim “clinically proven in assisting healthy blood glucose levels” in the target population of type 2 diabetics for its white mulberry-based dietary supplement. It will be just the second claim assessed by the UK Nutrition and Health Claims Committee which took over the role from EFSA on 1 January 2021 following Brexit.

Recruitment Begins For UK Health Claims Committee In Preparation For Brexit

With time running out for the UK to ratify its Withdrawal Agreement from the EU, the government has begun recruitment for a new Nutrition and Health Claims Committee which will take on the activities of EFSA in the event of a no deal.

European Trade Groups To Cosmetics Firms: Be Prepared For ‘No Deal’ Brexit

The UK is converting the EU’s Cosmetics Regulation and REACH into UK law, holding out hope that mutual interests will yield an arrangement for “frictionless trade.” However, the Cosmetic, Toiletry and Perfumery Association notes “the political landscape is very uncertain.”

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS139905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel